



## FOR IMMEDIATE RELEASE

### PPD Earns Accolades for Innovation in Employee Learning and Development

*Collaborative approach enhances performance, delivers value for biopharmaceutical clients*

WILMINGTON, N.C., (October 2, 2013) – Pharmaceutical Product Development, LLC ([PPD](#)) today announced the American Society for Training & Development (ASTD) has named PPD a 2013 ASTD BEST Award winner for excellence in [employee learning and development](#). PPD was honored for implementing innovative employee training programs, which drive efficiencies in the conduct of biopharmaceutical clients' drug development programs.

“Engaging and empowering employees help PPD consistently deliver value for clients,” said Mike Wilkinson, PPD’s executive vice president and chief information officer. “PPD takes a multifaceted, collaborative approach to employee learning. We blend novel concepts with an array of global resources to create learning and development programs that are flexible, customizable, technology-driven and responsive to an ever-changing business environment.”

PPD has enhanced [employee training and development](#) delivery options through collaboration between its human resources and [technology, innovation and performance](#) groups. Training modes – classroom, [virtual collaboration](#), mobile learning, self-study, e-learning, role playing, simulations and social learning – are adapted based on objectives and target employee audience.

The ASTD BEST Award follows PPD’s recent recognition for employee training, including the [Skillsoft Perspectives Innovation Award](#) for Empowering Learning Cultures in the Enterprise and [Training Top 125](#) honors for businesses that excel in employee learning and development.

As part of the ASTD BEST Awards, PPD leaders presented best practices to peers from a variety of industries during the annual Learn from the BEST seminar. PPD is featured in the October 2013 issue of [T+D](#), ASTD’s flagship magazine. To learn more about ASTD, visit [www.astd.org](#).

#### About PPD

PPD is a leading global [contract research organization](#) providing [drug discovery](#), development, lifecycle management and [laboratory](#) services. Our clients and partners include [pharmaceutical](#), [biotechnology](#), [medical device](#), academic and [government](#) organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit [www.ppdi.com](#).

#### Contacts

Media:

Lee Kennedy

+1 919 456 5350

[lee.kennedy@ppdi.com](mailto:lee.kennedy@ppdi.com)

Investors:

Luke Heagle

+1 910 558 7585

[luke.heagle@ppdi.com](mailto:luke.heagle@ppdi.com)

*Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD's ASTD BEST Award, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate and retain key personnel; competition in the outsourcing industry; PPD's ability to win new business; rapid technological advances that make our services less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.*

###